AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger
The Anglo-Swedish drugmaker’s flirtation with a grand combo with US group Bristol Myers Squibb is baffling• AstraZeneca shares fall 8.9% over merger talks with US cancer drug firmSir Pascal Soriot, chief executive of AstraZeneca, starts with huge credit in the bank, obviously. His long tenure has been a triumph, starting with the against-the-odds victory over Pfizer’s charmless accountants in 2014.The $39bn (£29bn) purchase of Alexion in 2021 looked a little over-priced at the time, but you could see how it…
Source: www.theguardian.com